Publication |
2016
Abstract
A treatment of breast cancer is undergoing important advances for last years, which lead to improvement of the prognosis and to extension their overall survival. Two new drugs (pertuzumab and trastuzumab emtansin) have been classified into a practice for patients with advanced HER2 positive breast tumor.
Experiences from the clinical practice confirmed the safety of both preparations and the profit for the patients.